Navigation Links
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target

any diabetes drug for an eight- week period. Patients were then randomized to receive one of four once-daily doses of liraglutide (0.1, 0.3, 0.6, and 0.9 mg) or placebo. Baseline A1c levels ranged between 8.1 to 8.5%. The randomized, 14-week study showed statistically significant dose-dependent reductions in A1c levels (ranging from 0.79 to 1.85 percentage points - placebo adjusted, p<0.0001) after once- daily dosing of liraglutide monotherapy in these patients. Further, A1c levels below 7 percent were achieved by 22, 43, 62 and 75 percent of patients receiving liraglutide 0.1, 0.3, 0.6 and 0.9 mg/day compared with 9 percent of those receiving placebo. Additionally, in these normal-weight subjects (average BMI 23.9) no relevant changes in body weight or major or minor hypoglycemic events occurred in any study group.(1)

The main gastrointestinal adverse events in the high dose group versus placebo were: constipation (7% versus 9%), diarrhea (9% versus 4%), gastritis (7% vs. 0%) and nausea (7% versus 2%). No subject had a treatment-related increase in liraglutide antibodies.

About liraglutide

Currently in phase 3 clinical trials, liraglutide is a human analog of the naturally occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is rapidly broken down in the body and thus not practical as a therapy for type 2 diabetes. GLP-1 is released from the gastrointestinal tract upon ingestion of food. When glucose levels become too high, GLP-1 triggers the release of insulin from the pancreas and decreases the secretion of glucagon, a hormone that promotes glucose synthesis in the liver. GLP-1 releases insulin in a glucose-dependent manner, meaning that it only triggers insulin secretion if blood glucose is too high. This characteristic is thought to result in a low risk of hypoglycemia, which has been confirmed in a number of studies in which GLP-1 was infused intravenously or subcutaneously.

Novo Nordisk is a healthcare company and a world lead
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/21/2014)... VIENNA, Va. , Nov. 21, 2014  Alta ... in Southern California , today announced ... technology. Alta will be providing the innovative BeClose system ... Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... providing the kind of affordable 24/7 care our clients ...
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
(Date:11/21/2014)... , 21. November 2014 ... heute bekannt gegeben, dass die Europäische ... die Kennzeichnung als Orphan-Medizinprodukt an Palovarotene ... Unternehmens zur Behandlung von Fibrodysplasia ossificans ... stark beeinträchtigende genetische Krankheit, die von ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Ga., Sept. 14, 2011 Greenway Medical Technologies, ... Inland Northwest Health Services (INHS) today announced an ... health record (EHR) and practice management solution ... practices requiring advanced care coordination and network interoperability. ...
... 14, 2011 Delcath Systems, Inc. (NASDAQ: ... sponsored an industry symposium at the Cardiovascular ... in Munich, Germany—the largest international forum for minimally ... radiologists in attendance. The event, held ...
Cached Medicine Technology:Greenway Partners With INHS to Advance EHR Adoption 2Greenway Partners With INHS to Advance EHR Adoption 3Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting 2Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting 3
(Date:11/23/2014)... The clinical trial report, "Aspergillosis Global ... the Aspergillosis clinical trial scenario. This report provides ... trials on Aspergillosis. It includes an overview of ... per the site of trial conduction across the ... disease clinical trials by their phase, trial status, ...
(Date:11/23/2014)... 23, 2014 The report, “Market ... to 2020 - Asia-Pacific” provides quantitative analysis of ... segments: minimally invasive body contouring devices, non-invasive body ... includes market size data by revenue and volume ... countries: China, Japan, South Korea, Australia and India. ...
(Date:11/23/2014)... 23, 2014 Nearly 260 testosterone ... strokes, deep vein thrombosis and other serious cardiovascular ... multidistrict litigation (MDL) underway in the Northern District ... Court documents updated on November 17th by the ... the filing of 259 lawsuits against the makers ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released ... products are available at low rates up to 30% ... the new emergency doors. The emergency door adopts fireproof ... from several colors. All of the products are top-quality ... is not as easy as many people think. ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are ... announced its new collection of power suppliers. Additionally, it ... power suppliers. All the new models come with big ... until Dec. 20, 2014. , SWAccessControl.com has thousands of ... it for a long time. It is very wise ...
Breaking Medicine News(10 mins):Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
... Make Breast Cancer ... Nov. 8 Washington State has the highest rate,of breast ... of Susan G. Komen for the Cure will host a ... policymakers to increase the budget for,screening programs for low-income women ...
... and OXFORD, England, November 8 /PRNewswire-FirstCall/,-- Evotec AG (Frankfurt Stock Exchange: ... on Tuesday, 13 November 2007. The Company is going to ... details: Date: Tuesday, 13 November 2007 Time: 02.00 p.m. ... 08.00 a.m. US time ...
... Nov. 8 World Diabetes Day, November 14,is observed ... 160 countries,and by others with an interest in diabetes. ... provides an excellent opportunity,to focus on the significant increase ... response. Funded by the National Institutes of Health ...
... Nov. 8 Repligen Corporation,(Nasdaq: RGEN ) today ... ended September 30, 2007. Total revenue for the quarter ... fiscal year,2007 ended September 30, 2006, an increase of ... of Protein A product revenue.,Gross profit on product revenue ...
... Healthcare professionals can now conduct immediate comprehensive general, health diagnosis ... ... than ever., UNION CITY, ... products company manufacturing point-of-care,blood analysis systems, announced today that the U.S. ...
... Nov. 8 Thoratec,Corporation initiated a worldwide ... Ventricular Assist Devices (IVAD) having Catalogue No.,10012-2555-001, ... and,distributed since October 2004. The current Instructions ... in the pre-peritoneal (internal) position or placed,in ...
Cached Medicine News:Health News:Puget Sound Komen for the Cure, Former First Lady Mona Locke, Washington Health Leaders and Breast Cancer Survivors Call for Action to Reduce State's High Breast Cancer Incidence 2Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 2Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 3Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 2Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 3Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 4Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 5Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 6Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 7Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 2Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 3Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 4Health News:URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device 2
This is designed to synthesize current cardiovascular research findings for busy physicians and healthcare professionals....
Sages™ is the handheld version of The Sages Manual, a reference for the fundamentals of Laparoscopy and GI Endoscopy. It is a classic manual from the world's most pioneering society of minimally...
... This reference for third and ... clerkships enables quick study and easy ... A perfect fit for a lab ... used as a quick review prior ...
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
Medicine Products: